Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Elicio Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +3 vs. Q2 2023
- Shares held
- 331.0K
- +45.2K (+15.8%) vs. Q2 2023
- Total value
- $2.80M
- +$81.5K (+3.0%) vs. Q2 2023
- New holders
- 3
- 6 more added
- Sold out
- 0
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $15.3M |
| Q1 2026 | 47 | $28.2M |
| Q4 2025 | 37 | $16.6M |
| Q3 2025 | 28 | $20.9M |
| Q2 2025 | 21 | $11.2M |
| Q1 2025 | 24 | $9.80M |
| Q4 2024 | 17 | $2.25M |
| Q3 2024 | 18 | $2.48M |
| Q2 2024 | 20 | $2.68M |
| Q1 2024 | 18 | $3.08M |
| Q4 2023 | 18 | $2.78M |
| Q3 2023 | 18 | $2.80M |
| Q2 2023 | 15 | $2.71M |
| Q1 2023 | 28 | $2.56M |
| Q4 2022 | 30 | $3.98M |
| Q3 2022 | 38 | $4.71M |
| Q2 2022 | 43 | $5.90M |
| Q1 2022 | 47 | $13.8M |
| Q4 2021 | 53 | $20.3M |
| Q3 2021 | 47 | $69.3M |
| Q2 2021 | 41 | $66.5M |
| Q1 2021 | 41 | $92.0M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Elicio Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 140,527 | $1.19M | 0.00% | +69,777+98.6% | Added |
| CM Management, LLC | 65,000 | $549.3K | 0.58% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 30,000 | $253.5K | 0.03% | −64,939−68.4% | Reduced |
| Geode Capital Management, LLC | 27,874 | $235.6K | 0.00% | +3,705+15.3% | Added |
| Millennium Management LLC | 20,380 | $172.2K | 0.00% | +20,380 | New |
| Citadel Advisors LLC | 16,206 | $136.9K | 0.00% | +16,206 | New |
| Meyer Handelman Co | 13,899 | $117.4K | 0.00% | +661+5.0% | Added |
| Bridgeway Capital Management, LLC | 12,500 | $105.6K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,681 | $14.2K | 0.00% | +96+6.1% | Added |
| Steward Partners Investment Advisory, LLC | 1,554 | $13.1K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 374 | $3.16K | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 350 | $3.00K | 0.00% | 00.0% | Unchanged |
| Northwest Capital Management Inc | 350 | $2.96K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 157 | $1.33K | 0.00% | +30+23.6% | Added |
| Tower Research Capital LLC (TRC) | 38 | $321 | 0.00% | −131−77.5% | Reduced |
| Wells Fargo & Company | 22 | $186 | 0.00% | +7+46.7% | Added |
| UBS Group AG | 16 | $135 | 0.00% | −629−97.5% | Reduced |
| Royal Bank of Canada | 57 | $0 | 0.00% | +57 | New |